Loading...
•
Dec 31, 2020
Sage Q4 2020 Earnings Report
Sage reported Q4 and full year 2020 financial results and highlighted pipeline and business progress.
Key Takeaways
Sage Therapeutics reported a net income of $974.9 million for the fourth quarter of 2020, driven by $1.1 billion in net revenue, primarily from a collaboration with Biogen. The company ended the year with a strong cash position of $2.1 billion.
Entered into a global collaboration with Biogen worth up to $3.1 billion.
Reported positive interim data from Phase 3 open-label SHORELINE Study.
Ended 2020 with a cash balance of $2.1 billion.
Initiated six late-stage clinical trials in 2020, including four Phase 3 trials.
Forward Guidance
Sage anticipates cash, cash equivalents, restricted cash, and marketable securities of more than $1.7 billion at end of 2021 and does not anticipate receipt of any milestone payments from collaborations in 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...